- $677.97m
- $625.73m
- $73.24m
- 99
- 16
- 86
- 75
Annual income statement for Iradimed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 31.7 | 41.8 | 53.3 | 65.6 | 73.2 |
| Cost of Revenue | |||||
| Gross Profit | 23.6 | 32 | 41.3 | 50.2 | 56.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 32.5 | 32 | 37.7 | 45.5 | 51.3 |
| Operating Profit | -0.756 | 9.82 | 15.6 | 20 | 22 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.617 | 9.84 | 16.2 | 21.7 | 24.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.569 | 9.33 | 12.8 | 17.2 | 19.2 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 1.37 | 9.33 | 12.8 | 17.2 | 19.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.37 | 9.33 | 12.8 | 17.2 | 19.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.046 | 0.741 | 1.02 | 1.35 | 1.5 |
| Dividends per Share | |||||
| Special Dividends per Share |